- 期刊
Fexofenadine HCI (Allegra)對於治療過敏性鼻炎效益與安全性評量的臨床試驗
Safety and Efficacy of Fexofenadine HCI (Allegra) in the Treatment of Allergic Rhinitis: Clinical Experience
摘要
Objective: Fexofenadine HCI (Allegra) is a new safe congener of the nonsedating H1 antagonists. It is an active metabolite of terfenadine. It has an established and valued place in the rapid symptomatic treatment of allergy without cardiogenic side effects. It is highly selective for H1 receptors and is devoid of sighificant anticholinergic actions. Poor penetration by the drug into the CNS appears to account for its low incidence of side effects. Patients and Methods: We studied 33 patients with allergic rhinitis (older than 12 years old) in this open label, randomized clinical trial. Patients with a symptom score (TSS) over 6 for sneezing, rhinorrhea, itchy nose and itchy eyes were selected for study. Fexofenadine 60 mg bid was given for 14 days. The efficacy, tolerance, and safety of the drug were evaluated. Result: One patient was lost to follow-up, for a total of 32 patients in the trial. In the efficacy trial, 30 out of 32 patients had good results. The tolerance for the drug was 94%. Only 4 patients had mild side effects as follows: one with headache, one with sedation, one with nausea, and one with fatigue. Conclusions: Fexofenadine is a safe H1 antagonist. Fexofenadine 60 mg bid is a new H1 antagonist with high efficacy and low risk. It is a good alternative for treatment of allergic rhinitis.
並列摘要
Objective: Fexofenadine HCI (Allegra) is a new safe congener of the nonsedating H1 antagonists. It is an active metabolite of terfenadine. It has an established and valued place in the rapid symptomatic treatment of allergy without cardiogenic side effects. It is highly selective for H1 receptors and is devoid of sighificant anticholinergic actions. Poor penetration by the drug into the CNS appears to account for its low incidence of side effects. Patients and Methods: We studied 33 patients with allergic rhinitis (older than 12 years old) in this open label, randomized clinical trial. Patients with a symptom score (TSS) over 6 for sneezing, rhinorrhea, itchy nose and itchy eyes were selected for study. Fexofenadine 60 mg bid was given for 14 days. The efficacy, tolerance, and safety of the drug were evaluated. Result: One patient was lost to follow-up, for a total of 32 patients in the trial. In the efficacy trial, 30 out of 32 patients had good results. The tolerance for the drug was 94%. Only 4 patients had mild side effects as follows: one with headache, one with sedation, one with nausea, and one with fatigue. Conclusions: Fexofenadine is a safe H1 antagonist. Fexofenadine 60 mg bid is a new H1 antagonist with high efficacy and low risk. It is a good alternative for treatment of allergic rhinitis.